<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00205751</url>
  </required_header>
  <id_info>
    <org_study_id>01-002-0601</org_study_id>
    <nct_id>NCT00205751</nct_id>
  </id_info>
  <brief_title>Thalidomide/Dexamethasone vs MP for Induction Therapy and Thalidomide/Intron A vs Intron A for Maintenance Therapy</brief_title>
  <official_title>International, Multi-center, Prospective, Double Randomized, Open Phase III Study Evaluating Thalidomide/Dexamethasone Versus Melphalan/Prednisone as Induction Therapy and Thalidomide/Interferon-alpha Versus Interferon-alpha as Maintenance Therapy in Newly Diagnosed Patients With Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Austrian Forum Against Cancer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Austrian Forum Against Cancer</source>
  <brief_summary>
    <textblock>
      This is an international multi-center prospective, double randomized, open, controlled phase
      III study with a phase II entrance phase to compare the therapeutic efficacy of thalidomide
      plus dexamethasone to conventional melphalan plus prednisone in newly diagnosed myeloma
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2001</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to progression</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Response rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Multiple Myeloma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide/Dexamethasone vs Melphalan/Prednisone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with Multiple Myeloma of IgG, IgA, IgD, IgE, IgM lambda or kappa light chain,
             low secretory or non-secretory disease

          -  WHO performance status 0,1,2,or 3

          -  No prior treatment of multiple myeloma

          -  Clear requirement of treatment (usually Durie/Salmon stage II or III)

          -  Anticipated life expectancy of at least 3 months

          -  Adequate organ function

          -  Minimum recovery period of 2 weeks following any major surgical procedure before entry
             into this study

          -  Women, who are sterilized via hysterectomy or bilateral tubal ligation or at least one
             year post-menopausal

          -  Age of at least 19 years, there is no upper age limit patients must have been informed
             and must have signed an informed consent

        Exclusion Criteria:

          -  Extramedullary plasmocytoma or solitary plasmocytoma without evidence of dissemination
             of disease

          -  Benign monoclonal gammopathy

          -  Multiple myeloma of IgM without osteolytic bone lesions

          -  Smouldering myeloma

          -  More than 3 irradiation fields

          -  Irreversible performance status of WHO4

          -  Prior treatment of myeloma with any of the following: chemotherapeutic or
             immunomodulatory agents, corticosteroids, antiangiogenic agents or other
             investigational drugs

          -  Women of childbearing potential

          -  Preexisting peripheral polyneuropathy

          -  Congestive heart failure NYHA III, IV

          -  Acute infection requiring systemic antibiotics at study entry until resolved

          -  Any uncontrolled underlying medical condition (eg diabetes, glaucoma)

          -  Second primary malignancy (with the exception of cervical carcinoma in situ and
             non-myeloma skin malignancies) unless patient has been disease-free for at least three
             years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heinz Ludwig, MD,Univ.Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wilhelminenspital 1st medical dep.-center for oncology and hematology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wilhelminenspital, 1st Medical Department-center for oncology and hematology</name>
      <address>
        <city>Vienna</city>
        <zip>1190</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>November 21, 2013</last_update_submitted>
  <last_update_submitted_qc>November 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2013</last_update_posted>
  <keyword>Multiple Myeloma</keyword>
  <keyword>first line treatment</keyword>
  <keyword>thalidomide</keyword>
  <keyword>melphalan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

